STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNTI
  4. [8-K] Senti Biosciences, Inc. Reports Material Event

[8-K] Senti Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SNTI logo
Senti Bioscience

NASDAQ:SNTI

SNTI Rankings

#5428 Ranked by Market Cap
N/A Ranked by Dividends

SNTI Latest News

Sep 2, 2025
Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Aug 14, 2025
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Aug 12, 2025
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Aug 7, 2025
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Aug 5, 2025
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia

SNTI Latest SEC Filings

Sep 2, 2025
[SCHEDULE 13D/A] Senti Biosciences, Inc. SEC Filing
Aug 7, 2025
[10-Q] Senti Biosciences, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Senti Biosciences, Inc. Reports Material Event
Jul 21, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity
Jul 21, 2025
[Form 3] Senti Biosciences, Inc. Initial Statement of Beneficial Ownership

SNTI Stock Data

38.46M
11.24M
57.04%
25.76%
1.07%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO